Merck paying off 3,100 families for heart attack/stroke deaths linked to Vioxx painkilling drug

vioxx blueDrug giant Merck & Co. is paying the families of more than 3,100 Vioxx painkiller users who died of heart attacks and strokes that were blamed on the drug. Merck introduced Vioxx in 1999 but withdrew it from the market in 2004 when a study showed the drug doubled the risk of heart attacks and strokes. By 2007, Merck had set up a fund of $4.85 billion (yes, that’s billion with a ‘B’)  to cover claims of death and lesser injuries, after reserving $1.9 billion to fight over 26,600 Vioxx lawsuits in court. Houston attorney Mark Lanier observed at the time:

“We don’t know any drug right now with this number of deaths associated with it. This is a very sad chapter in the tragedy of pharmaceutical companies gone wild.” 

And – quelle surprise! – Vioxx turns out to be one of countless prescription drugs that have been fraudulently promoted in industry-funded ghostwritten articles in medical journals.    Continue reading

Medical ghostwriting: if you’re not alarmed, maybe you’re just not paying attention

ghostwriting questions money I had to go have a little lie-down after I read the The New York Times story this week about the scandalous practice of  medical ghostwriting. Here’s how Danish researcher Dr. Peter Gøtzsche describes medical ghostwriting:  “Ghostwriting occurs when someone makes substantial contributions to a manuscript without attribution or  disclosure. It is considered bad publication practice in the  medical sciences, andsome argue it is scientific misconduct. At its extreme, medical ghostwriting involves pharmaceutical companies hiring professional writers to produce papers promoting their products–  but hiding those contributions and instead naming academic physicians or scientists as the authors.

Here’s an extreme example of extreme medical ghostwriting. The New York Times and the journal Public Library of Science Medicine have outlined recent court documents revealing that ghostwriters paid by drug giant Wyeth Pharmaceuticals played a major role in producing 26 scientific papers published in medical journals that backed the use of hormone replacement therapy in women. That supposed medical consensus benefited Wyeth directly, as sales of its HRT drugs Premarin and Prempro soared to nearly $2 billion by 2001.   Continue reading